Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01011 vs Xgeva in Solid Tumor Bone Metastases
CTR20210226Phase 3Completed
- Sponsor
- Boan Biotech
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of LY01011 in bone metastases, Nonhematologic neoplasms, sponsored by Boan Biotech. Started Feb 2021; status: completed.
02
Drugs
LY01011
03
Conditions
bone metastasesNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20210226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210226.